NovaBridge Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
The company has pivoted to a platform model leveraging China-U.S. synergies, with Givastomig showing strong efficacy and safety in gastric cancer and VIS-101 demonstrating superior durability in AMD. IPO plans are delayed pending regulatory and market conditions.
-
VIS-101 demonstrated strong safety, rapid and durable efficacy in phase IIa for retinal vascular diseases, with up to 70% of patients retreatment-free at four months. A phase IIb dose-ranging study is planned, and a global phase III program will follow, supported by a robust financial position.
Fiscal Year 2025
-
A major transformation is underway, shifting to a global platform model that leverages Asian biotech innovation for global markets. The pipeline features promising oncology and ophthalmology assets, with a focus on rapid proof-of-concept and capital-efficient development. CBC Group's expertise and a hub-and-spoke structure underpin growth and value creation.
-
Focused on U.S. clinical development, the lead asset Jeva Stomach shows strong efficacy and safety in front-line metastatic gastric cancer, with rapid trial enrollment and broad eligibility. A large phase two trial is set to launch, and expansion into other cancers is planned.
-
Givastomig, a bispecific 18.2/4-1BB antibody, showed an 83% ORR and favorable safety in frontline metastatic gastric cancer when added to standard IO chemo, with broad patient eligibility and manageable toxicity. Dose expansion and further data are expected in 2025–2026.
-
Giva, a Claudin 18.2/4-1BB bispecific, demonstrates promising efficacy and safety in frontline gastric cancer, with broad patient eligibility and a differentiated mechanism minimizing toxicity. Upcoming ESMO GI data and ongoing dose expansion aim to validate its potential as a new standard of care.
-
Recent strategic changes have refocused operations on US-based clinical development, with a strong cash position supporting a pipeline led by Giva, a Claudin 18.2 4-1BB bispecific antibody for gastric cancer. Key data releases are expected for Giva, Ragistomig, and ULI through 2025.
-
A major strategic shift in 2024 led to a U.S.-focused, capital-efficient operation advancing three clinical assets. Lead program givastomig shows strong efficacy and safety in gastric cancer, with key data readouts expected in late 2024 and early 2025. Uliledlimab and ragistomig also show promise, with pivotal data expected by 2026.
-
Significant transformation has positioned the company as a U.S.-focused precision oncology player with a robust clinical pipeline. Giva, a Claudin 18.2 4-1BB bispecific, is now the lead asset due to strong efficacy and safety data, with major readouts expected through 2026.
Fiscal Year 2024
-
The company has refocused as a U.S.-based, lean organization with three clinical-stage IO oncology assets. Givastomig shows strong efficacy and safety in gastric cancer, with expansion potential, while UliledlIMab and Ragistomig are advancing through key clinical milestones with data expected in 2025.
-
2024 saw a strategic transformation with the divestiture of China operations, a new U.S.-based leadership, and a streamlined focus on three immuno-oncology programs. Cash runway extends into 2027, supporting key clinical milestones for Uliledlimab and Givastomig.